Cipla Limited (CIPLA.NS)
NSE - NSE Real-time price. Currency in INR
Add to watchlist
911.35-2.15 (-0.24%)
At close: 3:30PM IST
| Previous close | 913.50 |
| Open | 917.45 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 909.90 - 920.50 |
| 52-week range | 706.50 - 1,005.00 |
| Volume | 912,057 |
| Avg. volume | 2,650,697 |
| Market cap | 735.264B |
| Beta (5Y monthly) | 0.44 |
| PE ratio (TTM) | 28.95 |
| EPS (TTM) | 31.48 |
| Earnings date | 26 Oct 2021 |
| Forward dividend & yield | 5.00 (0.55%) |
| Ex-dividend date | 09 Aug 2021 |
| 1y target est | 1,061.11 |
- PR Newswire
Cipla receives final approval for generic version of Novartis Pharmaceuticals Corporation Durezol® (Difluprednate Ophthalmic Emulsion 0.05%)
Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (hereafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05% from the United States Food and Drug Administration (US FDA).
- PR Newswire
Cipla receives final approval for generic version of Sunovion Pharmaceuticals, Inc.'s Brovana® (Arformoterol Tartrate Inhalation Solution 15 mcg/ 2mL)
Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (hereafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL from the United States Food and Drug Administration (US FDA).
© 2021 Verizon Media. All rights reserved.
